CG
RNAC icon

Cutler Group’s Cartesian Therapeutics RNAC Stock Holding History

Cutler Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-217
Closed -$3K – 5164
2020
Q2 		$3K Buy
+217
New +$19.7K ﹤0.01% 3647

Other funds holding RNAC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cutler Group's RNAC Position: Q1 2024 in Review

Cutler Group held its Cartesian Therapeutics (RNAC) position steady in Q1 2024 at 57 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2091.

Cutler Group first reported a position in RNAC in Q4 2018 and has held it in 19 quarters since. The position peaked at $7K in Q3 2021. 69 funds tracked by Wall St. Rank hold RNAC as of Q1 2024.

  • Cutler Group held 57 shares of Cartesian Therapeutics worth $1K as of Q1 2024.
  • Cutler Group left its Cartesian Therapeutics share count unchanged in Q1 2024.
  • Cartesian Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #2091 holding.
  • Cutler Group first reported a position in Cartesian Therapeutics in Q4 2018 and has held it in 19 quarters since.
  • Cutler Group's Cartesian Therapeutics position peaked at $7K in Q3 2021.
  • 69 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.